Clinical Trial Update: HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial updating on HM2014-26 DT2219 for relapsed or refractory B-lineage leukemia or lymphoma; study COMPLETED with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-lineage Leukemia
• B-lineage Lymphoma

Drugs mentioned

• DT2219 (DT2219)
• HM2014-26

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-13